MA32707B1 - Molecule d'anticorps amelioree - Google Patents

Molecule d'anticorps amelioree

Info

Publication number
MA32707B1
MA32707B1 MA33765A MA33765A MA32707B1 MA 32707 B1 MA32707 B1 MA 32707B1 MA 33765 A MA33765 A MA 33765A MA 33765 A MA33765 A MA 33765A MA 32707 B1 MA32707 B1 MA 32707B1
Authority
MA
Morocco
Prior art keywords
tocilizumab
molecule
pharmaceutical composition
antigens
strengthening
Prior art date
Application number
MA33765A
Other languages
Arabic (ar)
English (en)
Inventor
Tomoyuki Igawa
Shinya Ishii
Atsuhiko Maeda
Mika Sakurai
Tetsuo Kojima
Tatsuhiko Tachibana
Hirotake Shiraiwa
Hiroyuki Tsunoda
Yoshinobu Higuchi
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42059767&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32707(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of MA32707B1 publication Critical patent/MA32707B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)

Abstract

LES SÉQUENCES D'ACIDES AMINÉS D'UNE RÉGION VARIABLE ET D'UNE RÉGION CONSTANTE DE TOCILIZUMAB, QUI CONSTITUE UN ANTICORPS HUMANISÉ D'IGG1 ANTI-RÉCEPTEUR D'IL-6, SONT MODIFIÉES AFIN D'AMÉLIORER LES CARACTÉRISTIQUES PHARMACOCINÉTIQUES DU TOCILIZUMAB ET DE RENFORCER L'ACTIVITÉ DE NEUTRALISATION D'ANTIGÈNES DU TOCILIZUMAB. DE CETTE MANIÈRE, L'INVENTION PERMET DE PRODUIRE UNE MOLÉCULE DE DEUXIÈME GÉNÉRATION POUVANT ÊTRE ADMINISTRÉE À UNE FRÉQUENCE RÉDUITE, QUI PRÉSENTE UN EFFET THÉRAPEUTIQUE DURABLE ET DES PROPRIÉTÉS D'IMMUNOGÉNICITÉ, DE SÉCURITÉ ET PHYSIQUES AMÉLIORÉES (STABILITÉ ET UNIFORMITÉ), ET EST DE CE FAIT SUPÉRIEURE AU TOCILIZUMAB. L'INVENTION CONCERNE UNE COMPOSITION PHARMACEUTIQUE COMPRENANT LADITE MOLÉCULE, ET UN PROCÉDÉ DE PRODUCTION DE CETTE COMPOSITION PHARMACEUTIQUE.
MA33765A 2008-09-26 2011-04-12 Molecule d'anticorps amelioree MA32707B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2008248213 2008-09-26
JP2009060806 2009-03-13
JP2009067925 2009-03-19
PCT/JP2009/066590 WO2010035769A1 (fr) 2008-09-26 2009-09-25 Molécule d'anticorps améliorée

Publications (1)

Publication Number Publication Date
MA32707B1 true MA32707B1 (fr) 2011-10-02

Family

ID=42059767

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33765A MA32707B1 (fr) 2008-09-26 2011-04-12 Molecule d'anticorps amelioree

Country Status (36)

Country Link
US (11) US8562991B2 (fr)
EP (1) EP2330193B1 (fr)
JP (2) JP4550938B2 (fr)
KR (2) KR101044180B1 (fr)
CN (2) CN103254310B (fr)
AR (2) AR073404A1 (fr)
AU (1) AU2009290162B2 (fr)
BR (1) BRPI0905076B8 (fr)
CA (2) CA2763039C (fr)
CL (1) CL2011000632A1 (fr)
CO (1) CO6362048A2 (fr)
CR (1) CR20110204A (fr)
DK (1) DK2330193T3 (fr)
EC (1) ECSP11011003A (fr)
ES (1) ES2546800T3 (fr)
FI (1) FIC20210049I1 (fr)
FR (1) FR21C1054I2 (fr)
HR (1) HRP20150857T1 (fr)
HU (2) HUE027533T2 (fr)
IL (1) IL211850A0 (fr)
LT (1) LTC2330193I2 (fr)
LU (1) LUC00241I2 (fr)
MA (1) MA32707B1 (fr)
MX (1) MX2010003256A (fr)
MY (1) MY153908A (fr)
NL (1) NL301152I2 (fr)
NO (1) NO2021048I1 (fr)
NZ (1) NZ592214A (fr)
PE (1) PE20120079A1 (fr)
PL (1) PL2330193T3 (fr)
PT (1) PT2330193E (fr)
RU (1) RU2430111C3 (fr)
SI (1) SI2330193T1 (fr)
TW (1) TWI440469B (fr)
WO (1) WO2010035769A1 (fr)
ZA (1) ZA201103027B (fr)

Families Citing this family (154)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU736282B2 (en) 1997-03-21 2001-07-26 Chugai Seiyaku Kabushiki Kaisha A preventive or therapeutic agent for sensitized T cell- mediated diseases comprising IL-6 antagonist as an active ingredient
UA80091C2 (en) 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
AU2003271174A1 (en) 2003-10-10 2005-04-27 Chugai Seiyaku Kabushiki Kaisha Double specific antibodies substituting for functional protein
KR101374454B1 (ko) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
US8470316B2 (en) * 2005-10-14 2013-06-25 Chugai Seiyaku Kabushiki Kaisha Agents for suppressing damage to transplanted islets after islet transplantation
RU2450830C2 (ru) 2005-10-21 2012-05-20 Чугаи Сейяку Кабусики Кайся Средства для лечения кардиопатии
AR057582A1 (es) * 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
JP5033643B2 (ja) * 2006-01-27 2012-09-26 学校法人慶應義塾 脈絡膜血管新生を伴う疾患の治療剤
EP4793360A2 (fr) 2006-03-31 2026-08-19 Chugai Seiyaku Kabushiki Kaisha Procédés de régulation de la pharmacocinétique sanguine d'anticorps
JP5144499B2 (ja) 2006-03-31 2013-02-13 中外製薬株式会社 二重特異性抗体を精製するための抗体改変方法
JP5754875B2 (ja) 2006-04-07 2015-07-29 国立大学法人大阪大学 筋再生促進剤
MX2009007830A (es) 2007-01-23 2009-10-07 Univ Shinshu Inhibidor de rechazo cronico.
EP3127921A1 (fr) 2007-09-26 2017-02-08 Chugai Seiyaku Kabushiki Kaisha Procédé de modification d'un anticorps par point isoélectrique par substitution d'acide aminé dans cdr
ES2687808T3 (es) 2007-09-26 2018-10-29 Chugai Seiyaku Kabushiki Kaisha Región constante de anticuerpo modificado
TWI548418B (zh) 2007-12-05 2016-09-11 中外製藥股份有限公司 Anti-NR10 / IL-31RA antibody and its use
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
TW201920257A (zh) 2008-04-11 2019-06-01 日商中外製藥股份有限公司 重複結合複數個抗原的抗原結合分子
TW201503898A (zh) 2008-06-05 2015-02-01 Chugai Pharmaceutical Co Ltd 神經浸潤抑制劑
TWI440469B (zh) * 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
US20130064834A1 (en) 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
TWI544077B (zh) 2009-03-19 2016-08-01 中外製藥股份有限公司 Antibody constant region change body
JP5717624B2 (ja) 2009-03-19 2015-05-13 中外製薬株式会社 抗体定常領域改変体
TWI457134B (zh) * 2009-03-19 2014-10-21 Chugai Pharmaceutical Co Ltd Rheumatoid arthritis treatment
US20110117087A1 (en) 2009-10-26 2011-05-19 Reinhard Franze Method for the production of a glycosylated immunoglobulin
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
TWI667346B (zh) * 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的FcRn親和力之抗體
RS63800B1 (sr) 2010-05-28 2022-12-30 Chugai Pharmaceutical Co Ltd Poboljšanje antitumorskog odgovora t ćelije
CN103261222B (zh) * 2010-09-10 2017-07-28 医疗免疫有限公司 抗体衍生物
KR101933197B1 (ko) 2010-11-08 2018-12-27 제넨테크, 인크. 피하 투여용 항―ｉｌ―6 수용체 항체
CN105859889B (zh) 2010-11-17 2020-01-07 中外制药株式会社 具有代替凝血因子viii的功能的功能的多特异性抗原结合分子
TWI654203B (zh) 2010-11-30 2019-03-21 Chugai Seiyaku Kabushiki Kaisha 具有鈣依存性的抗原結合能力之抗體
US20140080153A1 (en) * 2011-01-07 2014-03-20 Chugai Seiyaku Kabushiki Kaisha Method for improving physical properties of antibody
CA2825778A1 (fr) 2011-01-28 2012-08-02 Sanofi Compositions pharmaceutiques comprenant des anticorps humains contre pcsk9
SG10201609665PA (en) 2011-02-25 2017-01-27 Chugai Pharmaceutical Co Ltd FcɣRIIb-SPECIFIC Fc ANTIBODY
CN103502274B (zh) 2011-03-03 2016-01-06 埃派斯进有限公司 抗-il-6受体抗体及其使用方法
MX2013011366A (es) * 2011-03-30 2014-05-12 Chugai Pharmaceutical Co Ltd Retencion de las moleculas de union al antigeno en el plasma sanguineo y metodo para modificar la inmunogenicidad.
JP5636331B2 (ja) * 2011-04-28 2014-12-03 シスメックス株式会社 ペプチドの遊離方法および回収方法
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
ES2773111T3 (es) 2011-09-16 2020-07-09 Regeneron Pharma Inhibidor de la proproteína convertasa subtilisina/kexina 9 (PCSK9) para su uso en la reducción de los niveles de lipoproteína (a)
JP6322411B2 (ja) 2011-09-30 2018-05-09 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
TW201817745A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
US9943594B2 (en) 2011-10-11 2018-04-17 Sanofi Biotechnology Methods for the treatment of rheumatoid arthritis
TWI589299B (zh) 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
KR20210074395A (ko) 2011-11-30 2021-06-21 추가이 세이야쿠 가부시키가이샤 면역 복합체를 형성하는 세포내로의 운반체（캐리어）를 포함하는 의약
EP4624490A3 (fr) 2012-02-09 2025-11-05 Chugai Seiyaku Kabushiki Kaisha Région fc modifiée d'anticorps
CA2865158C (fr) 2012-02-24 2022-11-01 Chugai Seiyaku Kabushiki Kaisha Molecule de liaison d'antigene destinee a favoriser la disparition d'antigene via le recepteur fc.gamma.riib
HUE037659T2 (hu) 2012-03-16 2018-09-28 Regeneron Pharma Hisztidinmódosított könnyûlánc antitestek és genetikailag módosított rágcsálók ennek az elõállítására
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
US9801362B2 (en) 2012-03-16 2017-10-31 Regeneron Pharmaceuticals, Inc. Non-human animals expressing pH-sensitive immunoglobulin sequences
WO2013138681A1 (fr) 2012-03-16 2013-09-19 Regeneron Pharmaceuticals, Inc. Souris produisant des protéines de liaison à l'antigène ayant des caractéristiques de liaison dépendant du ph
KR101525919B1 (ko) * 2012-05-11 2015-06-03 가톨릭대학교 산학협력단 자가면역 질환 예방 및 치료를 위한 ｔｎｆｒ２를 기반으로 하는 이중 항체
NZ704771A (en) * 2012-08-13 2018-02-23 Regeneron Pharma Anti-pcsk9 antibodies with ph-dependent binding characteristics
TWI855488B (zh) 2012-08-24 2024-09-11 日商中外製藥股份有限公司 FcγRIIb特異性Fc區域變異體
US20150239970A1 (en) * 2012-10-25 2015-08-27 Medimmune, Llc Stable, Low Viscosity Antibody Formulation
SG11201508170TA (en) 2013-04-02 2015-11-27 Chugai Pharmaceutical Co Ltd Fc REGION VARIANT
US10111953B2 (en) 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
TW201534324A (zh) 2013-06-07 2015-09-16 Sanofi Sa 藉由投與ｐｃｓｋ９抑制劑抑制動脈粥狀硬化的方法
EP3009518B1 (fr) 2013-06-11 2020-08-12 National Center of Neurology and Psychiatry Procédé permettant de prédire le pronostic post-thérapie d'un patient atteint de sclérose en plaques à périodes progressives et rémittentes (spppr) et procédé permettant de déterminer l'applicabilité d'une nouvelle thérapie
CA2925256C (fr) 2013-09-27 2023-08-15 Chugai Seiyaku Kabushiki Kaisha Procede de production d'un heteromultimere polypeptidique
US10428157B2 (en) 2013-11-12 2019-10-01 Sanofi Biotechnology Dosing regimens for use with PCSK9 inhibitors
US10105418B2 (en) * 2013-12-23 2018-10-23 Staley A. Brod Oral administration of tocilizumab treatment of autoimmune disease
WO2015141862A1 (fr) 2014-03-17 2015-09-24 Mitsubishi Tanabe Pharma Corporation Conjugués anticorps-fynomer
KR20230074283A (ko) 2014-07-16 2023-05-26 사노피 바이오테크놀로지 이형접합성 가족성 고콜레스테롤혈증(heFH) 환자의 치료방법
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
EP3234120B1 (fr) 2014-12-15 2025-09-03 The Regents of the University of California Molécules cytotoxiques réagissant à des ligands intracellulaires pour la destruction sélective médiée par les lymphocytes t
WO2016100232A1 (fr) 2014-12-15 2016-06-23 The Regents Of The University Of California Récepteur d'antigène chimère de type porte ou bispécifique sensible à cd19 et à cd20
MX2017005774A (es) 2014-12-19 2017-07-28 Chugai Pharmaceutical Co Ltd Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso.
EA201791366A1 (ru) 2014-12-19 2018-02-28 Чугаи Сейяку Кабусики Кайся Антитела к c5 и способы их применения
CN114773469B (zh) 2015-02-05 2025-12-19 中外制药株式会社 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用
TWI759261B (zh) * 2015-02-27 2022-04-01 日商中外製藥股份有限公司 Ｉｌ－６受體抗體用於製備醫藥組成物的用途
JP6875683B2 (ja) 2015-05-19 2021-05-26 国立研究開発法人国立精神・神経医療研究センター 多発性硬化症（ｍｓ）患者の新規治療適用判断方法
EA201890519A1 (ru) 2015-08-18 2018-07-31 Ридженерон Фармасьютикалз, Инк. Ингибирующие антитела против pcsk9 для лечения пациентов с гиперлипидемией, подвергающихся аферезу липопротеинов
US10266590B2 (en) 2015-09-04 2019-04-23 Momenta Pharmaceuticals, Inc. Methods related to biologics
EP3368571B1 (fr) 2015-10-30 2022-12-07 The Regents of The University of California Polypeptides sensibles au facteur de croissance transformant bêta et leurs procédés d'utilisation
WO2017096331A1 (fr) 2015-12-04 2017-06-08 Juno Therapeutics, Inc. Méthodes et compositions liées à la toxicité associée à la thérapie cellulaire
EP3394098A4 (fr) 2015-12-25 2019-11-13 Chugai Seiyaku Kabushiki Kaisha Anticorps anti-myostatine et procédés d'utilisation
SG11201803989WA (en) 2015-12-28 2018-06-28 Chugai Pharmaceutical Co Ltd Method for promoting efficiency of purification of fc region-containing polypeptide
CN109476743A (zh) 2016-03-22 2019-03-15 西雅图儿童医院(以西雅图儿童研究所名义营业) 预防或缓解毒性的早期干预方法
AU2017255077B2 (en) 2016-04-28 2024-05-16 Chugai Seiyaku Kabushiki Kaisha Antibody-containing preparation
WO2017201731A1 (fr) * 2016-05-27 2017-11-30 Beijing Vdjbio Co., Ltd. Anticorps, composition et kits les comprenant et leurs procédés d'utilisation
US20200306283A1 (en) 2016-06-22 2020-10-01 William Warren HARLESS Cancer treatment and metastasis inhibition using an anti-cancer stem cell agent in combination with a neu1 sialidase inhibitor or a cytokine inhibitor after primary cancer treatment
CN116271014A (zh) 2016-08-05 2023-06-23 中外制药株式会社 用于预防或治疗il-8相关疾病的组合物
CA3039136A1 (fr) * 2016-09-02 2018-03-08 The Regents Of The University Of California Methodes et compositions impliquant des fragments variables a chaine unique (scfv) de liaison au recepteur alpha de l'interleukine-6
US20200078400A1 (en) 2016-12-03 2020-03-12 Juno Therapeutics, Inc. Methods for determining car-t cells dosing
WO2018112232A1 (fr) 2016-12-14 2018-06-21 Progenity Inc. Traitement d'une maladie du tractus gastro-intestinal avec un inhibiteur des interleukines il-12/il-23 libéré à l'aide d'un dispositif ingérable
CA3045310A1 (fr) 2016-12-14 2018-06-21 Progenity, Inc. Traitement d'une maladie du tractus gastro-intestinal avec une chimoikine/un inhibiteur du recepteur de chimiokine
WO2018112237A1 (fr) 2016-12-14 2018-06-21 Progenity Inc. Traitement d'une maladie du tractus gastro-intestinal avec un inhibiteur de l'il -6 r
WO2018139623A1 (fr) 2017-01-30 2018-08-02 Chugai Seiyaku Kabushiki Kaisha Anticorps anti-sclérostine et procédés d'utilisation
JP7630906B2 (ja) 2017-02-01 2025-02-18 イェール・ユニヴァーシティー 利尿薬耐性の治療
MX2019010171A (es) 2017-02-27 2019-10-15 Juno Therapeutics Inc Composiciones, articulos de fabricacion y metodos relacionados con la dosificacion en la terapia celular.
CA3054632A1 (fr) 2017-03-30 2018-10-04 Progenity, Inc. Traitement d'une maladie du tractus gastro-intestinal avec un agent immunomodulateur libere a l'aide d'un dispositif ingerable
CN114989305A (zh) * 2017-03-31 2022-09-02 北京智仁美博生物科技有限公司 新型双特异性抗体及其用途
EP3620531A4 (fr) 2017-05-02 2021-03-17 National Center of Neurology and Psychiatry Procédé de prédiction et d'évaluation d'un effet thérapeutique dans des maladies associées à il-6 et à des neutrophiles
EP3631468A1 (fr) 2017-06-02 2020-04-08 Juno Therapeutics, Inc. Articles de fabrication et procédés liés à la toxicité associée à la thérapie cellulaire
IL327498A (en) 2017-06-02 2026-05-01 Juno Therapeutics Inc Articles of manufacture and methods for treatment using adoptive cell therapy
WO2019046832A1 (fr) 2017-09-01 2019-03-07 Juno Therapeutics, Inc. Expression génique et évaluation d'un risque de développement d'une toxicité suite à une thérapie cellulaire
WO2019078344A1 (fr) 2017-10-20 2019-04-25 学校法人兵庫医科大学 Composition médicinale contenant un anticorps du recepteur anti-il -6 pour prévenir l'adhérence post-chirurgicale
WO2019089848A1 (fr) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Procédés associés à une charge tumorale pour évaluer une réponse à une thérapie cellulaire
KR20260090008A (ko) 2017-11-01 2026-06-16 추가이 세이야쿠 가부시키가이샤 생물 활성이 저하된 항체 배리언트 및 아이소폼
MA51210A (fr) 2017-12-01 2020-10-07 Juno Therapeutics Inc Procédés de dosage et de modulation de cellules génétiquement modifiées
SG11202006157VA (en) 2018-01-05 2020-07-29 Corvidia Therapeutics Inc Methods for treating il-6 mediated inflammation without immunosuppression
TWI822728B (zh) 2018-01-31 2023-11-21 加藤元一 含有il-6抑制劑的哮喘治療劑
WO2019170845A1 (fr) 2018-03-09 2019-09-12 Ospedale San Raffaele S.R.L. Antagoniste de l'il-1 et toxicité induite par la thérapie cellulaire
US20230041197A1 (en) 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
WO2019246271A1 (fr) 2018-06-20 2019-12-26 Progenity, Inc. Traitement d'une maladie du tractus gastro-intestinal avec un inhibiteur d'il-12/il-23
US12227565B2 (en) 2018-06-20 2025-02-18 Biora Therapeutics, Inc. Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine
KR20260109977A (ko) 2018-08-29 2026-07-13 리제너론 파아마슈티컬스, 인크. 류마티스성 관절염을 갖는 대상체를 치료하기 위한 방법 및 조성물
KR20210110811A (ko) 2018-11-30 2021-09-09 주노 쎄러퓨티크스 인코퍼레이티드 입양 세포 요법에서 ｂ 세포 악성 종양의 투약 및 치료 방법
EP4427810A3 (fr) 2018-11-30 2024-12-04 Juno Therapeutics, Inc. Procédés de traitement utilisant une thérapie cellulaire adoptive
KR20250116790A (ko) 2018-12-12 2025-08-01 카이트 파마 인코포레이티드 키메라 항원 수용체 및 car-t 세포 및 사용 방법
JP7542543B2 (ja) 2019-01-31 2024-08-30 サノフィ・バイオテクノロジー 若年性特発性関節炎を治療するための抗ｉｌ－６受容体抗体
JPWO2020202839A1 (fr) * 2019-03-29 2020-10-08
AU2020259884A1 (en) 2019-04-17 2021-10-07 Chugai Seiyaku Kabushiki Kaisha Therapeutic agent for urological cancer which is characterized by being administered with il-6 inhibitor and ccr2 inhibitor in combination
JP2022545312A (ja) 2019-04-24 2022-10-27 サノフィ・バイオテクノロジー 関節リウマチの診断及び処置の方法
CN114206346A (zh) 2019-05-03 2022-03-18 凯德药业股份有限公司 施用嵌合抗原受体免疫疗法的方法
WO2020243479A1 (fr) 2019-05-31 2020-12-03 The Johns Hopkins University Agents de liaison bispécifiques
CA3142710A1 (fr) 2019-06-04 2020-12-10 Sanofi Biotechnology Compositions et procedes de traitement de la douleur chez des sujets atteints de polyarthrite rhumatoide
CN114375205A (zh) 2019-06-20 2022-04-19 武田药品工业株式会社 用基于病毒的基因疗法进行治疗的方法
IL292665B2 (en) 2019-11-06 2026-02-01 Kite Pharma Inc Chimeric antigen receptor T cell therapy
EP4070097A1 (fr) 2019-12-06 2022-10-12 Juno Therapeutics, Inc. Procédés liés à la toxicité et à la réponse associées à une thérapie cellulaire pour le traitement de tumeurs malignes des lymphocytes b
WO2021150970A1 (fr) 2020-01-22 2021-07-29 H. Lee Moffitt Cancer Center And Research Institute, Inc. Lymphocytes t de récepteur antigénique chimérique bispécifique ciblant cd83 et le récepteur de l'interleukine 6
WO2021168375A1 (fr) 2020-02-20 2021-08-26 Kite Pharma, Inc. Thérapie par lymphocytes t à récepteurs antigéniques chimériques
MX2022010957A (es) 2020-03-03 2023-01-24 Twentyeight Seven Inc Compuestos que se dirigen a las proteínas de unión al arn o a las proteínas modificadoras del arn.
WO2021177980A1 (fr) 2020-03-06 2021-09-10 Genentech, Inc. Polythérapie contre le cancer comprenant un antagoniste de liaison à l'axe pd-1 et un antagoniste de l'il 6
EP4107184A1 (fr) 2020-03-23 2022-12-28 Genentech, Inc. Méthode de traitement d'une pneumonie, y compris la pneumonie à covid-19, avec un antagoniste de l'il6
EP4107186A1 (fr) 2020-03-23 2022-12-28 Genentech, Inc. Polythérapie à base de tocilizumab et de remdesivir pour une pneumonie à covid-19
JP2023518814A (ja) 2020-03-23 2023-05-08 ジェネンテック， インコーポレイテッド Ｃｏｖｉｄ－１９肺炎における、ｉｌ－６アンタゴニストに対する応答を予測するためのバイオマーカー
US20230192872A1 (en) * 2020-04-01 2023-06-22 The University Of Chicago Tocilizumab for the treatment of viral infections
AU2021274836A1 (en) 2020-05-19 2023-01-05 Aarhus Universitet Lysm receptor motifs
US12558423B2 (en) 2020-05-29 2026-02-24 Chugai Seiyaku Kabushiki Kaisha Antibody-containing formulation
BR112023000711A2 (pt) * 2020-07-17 2023-01-31 Daiichi Sankyo Co Ltd Método para produzir uma composição de conjugado de anticorpo-fármaco, e, composição de conjugado de anticorpo-fármaco
WO2022060412A1 (fr) 2020-09-17 2022-03-24 Genentech, Inc. Résultats de l'empacta : une étude multicentre, randomisée, en double aveugle, contrôlée par placebo, destinée à évaluer l'efficacité et la sécurité du tocilizumab chez des patients hospitalisés présentant une pneumonie à covid-19
WO2022165419A1 (fr) 2021-02-01 2022-08-04 Kyverna Therapeutics, Inc. Méthodes pour augmenter la fonction des lymphocytes t
JP2024507199A (ja) 2021-02-20 2024-02-16 カイト ファーマ インコーポレイテッド 免疫療法を選択するための遺伝子マーカー
CN117320749A (zh) * 2021-03-12 2023-12-29 中外制药株式会社 用于治疗或预防重症肌无力的药物组合物
BR112023019066A2 (pt) * 2021-03-25 2023-10-17 Chugai Pharmaceutical Co Ltd Método para selecionar pacientes com hipertensão arterial pulmonar e biomarcador
KR20230173179A (ko) 2021-05-14 2023-12-26 카이트 파마 인코포레이티드 키메라 항원 수용체 t세포 요법
WO2023119638A1 (fr) * 2021-12-24 2023-06-29 Chugai Seiyaku Kabushiki Kaisha Traitement d'une maladie démyélinisante du système nerveux central (snc) par du satralizumab
WO2023095854A1 (fr) * 2021-11-26 2023-06-01 Chugai Seiyaku Kabushiki Kaisha Traitement d'une maladie démyélinisante du système nerveux central (snc) avec du satralizumab
WO2023095305A1 (fr) * 2021-11-26 2023-06-01 Chugai Seiyaku Kabushiki Kaisha Traitement d'une maladie démyélinisante du système nerveux central (snc) à l'aide de satralizumab
TW202337495A (zh) 2022-01-19 2023-10-01 日商中外製藥股份有限公司 用satralizumab治療自體免疫腦炎
CN118742810A (zh) 2022-02-15 2024-10-01 凯德药业股份有限公司 从免疫疗法预测不良事件
CN116355825A (zh) * 2022-02-25 2023-06-30 南京工业大学 一种强化纤维素合成来提高人表皮生长因子分泌生产效率的方法
US20240190978A1 (en) 2022-11-15 2024-06-13 CSBioAsset LLC Compositions and methods for immunomodulatory bifunctional fusion molecules
WO2024126805A1 (fr) 2022-12-15 2024-06-20 Aarhus Universitet Activation synthétique de récepteurs transmembranaires multimères
CN120917153A (zh) 2023-03-17 2025-11-07 凯德药业股份有限公司 肿瘤微环境对免疫疗法疗效的影响
KR20260005947A (ko) 2023-04-28 2026-01-12 추가이 세이야쿠 가부시키가이샤 갑상선 안구 질환의 사트랄리주맙에 의한 치료
US20250290154A1 (en) 2024-03-04 2025-09-18 Kite Pharma, Inc. Predictive markers for immunotherapy
WO2025198912A1 (fr) 2024-03-21 2025-09-25 Hoffmann-La Roche Inc. Méthodes de traitement de la myasthénie grave
CN120818056A (zh) * 2024-04-15 2025-10-21 北京伟德杰生物科技有限公司 抗白介素6受体的抗体及其应用
WO2025225719A1 (fr) * 2024-04-26 2025-10-30 Chugai Seiyaku Kabushiki Kaisha Traitement et prévention de la dystrophie musculaire et de ses maladies ou troubles associés avec du satralizumab
CN122251624A (zh) * 2024-12-19 2026-06-23 北京伟德杰生物科技有限公司 抗体药物偶联物及其用途

Family Cites Families (212)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5144499B1 (fr) 1970-08-29 1976-11-29
JPS5334319B2 (fr) 1971-12-28 1978-09-20
JPS5717624B2 (fr) 1974-04-17 1982-04-12
JPS5484060A (en) 1977-12-12 1979-07-04 Kyushu Sekisui Kogyo Treatment of raw *wakame* by using chlorella extract
US4324710A (en) 1980-10-02 1982-04-13 The Firestone Tire & Rubber Company Naturally occurring thermoplastic resins as a substitute for various petroleum-derived materials in rubber stocks
US4769320A (en) 1982-07-27 1988-09-06 New England Medical Center Hospitals, Inc. Immunoassay means and methods useful in human native prothrombin and human abnormal prothorombin determinations
US4689299A (en) 1982-09-30 1987-08-25 University Of Rochester Human monoclonal antibodies against bacterial toxins
JPH06104071B2 (ja) 1986-08-24 1994-12-21 財団法人化学及血清療法研究所 第▲ｉｘ▼因子コンホメ−シヨン特異性モノクロ−ナル抗体
US4801687A (en) 1986-10-27 1989-01-31 Bioprobe International, Inc. Monoclonal antibody purification process using protein A
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5670373A (en) * 1988-01-22 1997-09-23 Kishimoto; Tadamitsu Antibody to human interleukin-6 receptor
US5322678A (en) * 1988-02-17 1994-06-21 Neorx Corporation Alteration of pharmacokinetics of proteins by charge modification
BG60017B2 (bg) 1988-09-28 1993-06-30 Eli Lilly And Company Метод за намаляване хетерогенността на моноклонални антитела
US5126250A (en) * 1988-09-28 1992-06-30 Eli Lilly And Company Method for the reduction of heterogeneity of monoclonal antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5202253A (en) 1988-12-30 1993-04-13 Oklahoma Medical Research Foundation Monoclonal antibody specific for protein C and antibody purification method
JPH0636741B2 (ja) 1989-11-08 1994-05-18 帝人株式会社 ヒト・プロテインｃの分離方法
CA2075927A1 (fr) 1990-02-16 1991-08-17 Victor A. Raso Reactifs hybrides ayant un pouvoir de liberation selective de molecules dans les cellules
AU668349B2 (en) 1991-04-25 1996-05-02 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin 6 receptor
US6136310A (en) 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
WO1994029471A1 (fr) 1993-06-10 1994-12-22 Genetic Therapy, Inc. Vecteurs adenoviraux pour le traitement de l'hemophilie
IL107742A0 (en) 1993-11-24 1994-02-27 Yeda Res & Dev Chemically-modified binding proteins
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5945311A (en) * 1994-06-03 1999-08-31 GSF--Forschungszentrumfur Umweltund Gesundheit Method for producing heterologous bi-specific antibodies
DE4419399C1 (de) 1994-06-03 1995-03-09 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von heterologen bispezifischen Antikörpern
US8017121B2 (en) * 1994-06-30 2011-09-13 Chugai Seiyaku Kabushika Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
US6309636B1 (en) * 1995-09-14 2001-10-30 Cancer Research Institute Of Contra Costa Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
AU700819B2 (en) 1994-10-07 1999-01-14 Chugai Seiyaku Kabushiki Kaisha Rheumatoid arthritis remedy containing IL-6 antagonist as effective component
PL182089B1 (en) 1994-10-21 2001-11-30 Chugai Pharmaceutical Co Ltd Pharmaceutic compositions for treating diseases caused by production of il-6
US6485943B2 (en) 1995-01-17 2002-11-26 The University Of Chicago Method for altering antibody light chain interactions
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5830478A (en) 1995-06-07 1998-11-03 Boston Biomedical Research Institute Method for delivering functional domains of diphtheria toxin to a cellular target
US5783186A (en) 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
TW518219B (en) 1996-04-26 2003-01-21 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
NZ333650A (en) 1996-07-19 2000-02-28 Amgen Inc Analogs of cationic proteins like NT-3 (neurotrophin-3) and BDNF (brain derived neurotrophic factor) that are circulated more readily due to a lower isoelectric point and a lower protein charge relative to the native protein
US5990286A (en) 1996-12-18 1999-11-23 Techniclone, Inc. Antibodies with reduced net positive charge
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
AU736282B2 (en) 1997-03-21 2001-07-26 Chugai Seiyaku Kabushiki Kaisha A preventive or therapeutic agent for sensitized T cell- mediated diseases comprising IL-6 antagonist as an active ingredient
US20070059302A1 (en) * 1997-04-07 2007-03-15 Genentech, Inc. Anti-vegf antibodies
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
KR20040024561A (ko) 1997-08-15 2004-03-20 츄가이 세이야꾸 가부시키가이샤 항 인터루킨-6 수용체 항체를 유효성분으로서 함유하는전신성 홍반성 낭창의 예방 및/또는 치료제
US20020187150A1 (en) * 1997-08-15 2002-12-12 Chugai Seiyaku Kabushiki Kaisha Preventive and/or therapeutic agent for systemic lupus erythematosus comprising anti-IL-6 receptor antibody as an active ingredient
AU750453B2 (en) * 1997-10-03 2002-07-18 Chugai Seiyaku Kabushiki Kaisha Natural human antibody
BR9908226A (pt) 1998-02-25 2000-10-24 Lexigen Pharm Corp Melhoramento da meia vida de circulação de proteìnas de fusão com base em anticorpo
ATE383875T1 (de) * 1998-03-17 2008-02-15 Chugai Pharmaceutical Co Ltd Prophylaktische oder therapeutische mittel gegen entzündliche erkrankungen des verdauungstraktes enthaltend antagonistische il-6 rezeptor antikörper
SK14812000A3 (sk) 1998-04-03 2001-08-06 Chugai Seiyaku Kabushiki Kaisha Chimérny reťazec protilátky, chimérna protilátka, v oblasť, humanizovaný reťazec protilátky, humanizovaná protilátka, dna, expresný vektor, hostiteľ, spôsob prípravy a liečivo
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
JP2002522063A (ja) * 1998-08-17 2002-07-23 アブジェニックス インコーポレイテッド 増加した血清半減期を有する改変された分子の生成
US6475718B2 (en) 1998-09-08 2002-11-05 Schering Aktiengesellschaft Methods and compositions for modulating the interaction between the APJ receptor and the HIV virus
WO2000032634A1 (fr) * 1998-12-01 2000-06-08 Protein Design Labs, Inc. Anticorps anti-interferon gamma humanises
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6972125B2 (en) 1999-02-12 2005-12-06 Genetics Institute, Llc Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith
SK782002A3 (en) * 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
SE9903895D0 (sv) 1999-10-28 1999-10-28 Active Biotech Ab Novel compounds
JP2004511426A (ja) 2000-05-03 2004-04-15 ミュンヘン　バイオテク　アーゲー 活性化血管部位に関連する陽イオン性の診断薬、画像化剤、および治療薬
AU2001268427B2 (en) 2000-06-16 2007-03-29 Glaxosmithkline Intellectual Property Limited Antibodies that immunospecifically bind to blys
AU1095202A (en) 2000-10-25 2002-05-06 Chugai Pharmaceutical Co Ltd Preventives or remedies for psoriasis containing as the active ingredient il-6 antagonist
JP4889187B2 (ja) * 2000-10-27 2012-03-07 中外製薬株式会社 Ｉｌ−６アンタゴニストを有効成分として含有する血中ｍｍｐ−３濃度低下剤
JP3899804B2 (ja) * 2000-11-27 2007-03-28 富士ゼロックス株式会社 画像処理装置、画像処理方法および画像処理プログラムを記録した記憶媒体
EP1355919B1 (fr) 2000-12-12 2010-11-24 MedImmune, LLC Molecules a demi-vies longues, compositions et utilisations de celles-ci
DK1366067T3 (da) 2001-03-07 2012-10-22 Merck Patent Gmbh Ekspressionsteknologi for proteiner indeholdende en hybrid isotype-antistof-enhed
UA80091C2 (en) 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
EP1423431B1 (fr) * 2001-04-13 2010-06-16 Biogen Idec MA Inc. Anticorps anti-vla-1
US7667004B2 (en) 2001-04-17 2010-02-23 Abmaxis, Inc. Humanized antibodies against vascular endothelial growth factor
EP1411118B1 (fr) * 2001-06-22 2008-09-03 Chugai Seiyaku Kabushiki Kaisha Inhibiteurs de proliferation cellulaire renfermant un anticorps anti-glypicane 3
US20040161741A1 (en) 2001-06-30 2004-08-19 Elazar Rabani Novel compositions and processes for analyte detection, quantification and amplification
US20030049203A1 (en) 2001-08-31 2003-03-13 Elmaleh David R. Targeted nucleic acid constructs and uses related thereto
BRPI0214168B8 (pt) 2001-11-14 2021-05-25 Centocor Inc anticorpos anti-il-6, moléculas de ácido nucleico codificando os mesmos, vetores compreendendo as referidas moléculas, composições e formulações compreendendo os referidos anticorpos, bem como métodos de produção dos mesmos
MXPA04007583A (es) 2002-02-11 2005-04-25 Genentech Inc Variantes de anticuerpo con tasas mas rapidas de asociacion a antigeno.
WO2003068260A1 (fr) * 2002-02-14 2003-08-21 Chugai Seiyaku Kabushiki Kaisha Produits pharmaceutiques en solution contenant des anticorps
AR038568A1 (es) 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
WO2003107218A1 (fr) 2002-05-31 2003-12-24 セレスター・レキシコ・サイエンシズ株式会社 Dispositif de prediction d'interactions
AU2003256266A1 (en) * 2002-06-12 2003-12-31 Genencor International, Inc. Methods and compositions for milieu-dependent binding of a targeted agent to a target
ATE426815T1 (de) 2002-06-12 2009-04-15 Genencor Int Verfahren zur verbesserung einer bindungseigenschaft eines molekuls
JP3856734B2 (ja) 2002-06-28 2006-12-13 株式会社日立製作所 多発性硬化症に対するインターフェロン・ベータ薬物治療の有効性予測方法
AU2003264009A1 (en) 2002-08-15 2004-03-03 Epitomics, Inc. Humanized rabbit antibodies
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
ATE480562T1 (de) 2002-10-15 2010-09-15 Facet Biotech Corp Veränderung von fcrn-bindungsaffinitäten oder von serumhalbwertszeiten von antikörpern mittels mutagenese
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
DK1575517T3 (da) 2002-12-24 2012-05-14 Rinat Neuroscience Corp Anti-ngf-antistoffer og fremgangsmåder til anvendelse af samme
US7223393B2 (en) 2003-02-07 2007-05-29 Pdl Biopharma, Inc Amphiregulin antibodies and their use to treat cancer and psoriasis
WO2004076485A1 (fr) 2003-02-28 2004-09-10 Lonza Biologics Plc. Purification d'anticorps par chromatographie d'affinite sur proteine a et chromatographie par echange d'ions
CN1798767B (zh) 2003-04-10 2011-02-16 晶面生物技术公司 通过诱变来改变抗体对FcRn的结合亲和力或血清半衰期
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
JP4759513B2 (ja) * 2003-06-02 2011-08-31 リキッド・マシンズ・インコーポレーテッド 動的、分散的および協働的な環境におけるデータオブジェクトの管理
ES2537738T3 (es) 2003-06-05 2015-06-11 Genentech, Inc. Terapia de combinación para trastornos de células B
EP1636264A2 (fr) 2003-06-24 2006-03-22 MERCK PATENT GmbH Molecules de recepteur du facteur de necrose tumorale a immunogenicite reduite
EP1644416A4 (fr) 2003-06-30 2007-08-29 Centocor Inc Proteines derivees de l'immunoglobuline anti-cible et genetiquement modifiees, compositions, procedes et utilisations
AU2004273791A1 (en) 2003-09-05 2005-03-31 Genentech, Inc. Antibodies with altered effector functions
JP2005101105A (ja) 2003-09-22 2005-04-14 Canon Inc 位置決め装置、露光装置、デバイス製造方法
AU2003271174A1 (en) * 2003-10-10 2005-04-27 Chugai Seiyaku Kabushiki Kaisha Double specific antibodies substituting for functional protein
AU2003271186A1 (en) 2003-10-14 2005-04-27 Chugai Seiyaku Kabushiki Kaisha Double specific antibodies substituting for functional protein
MXPA06003768A (es) 2003-10-17 2006-06-23 Chugai Pharmaceutical Co Ltd Agente terapeutico para el mesotelioma.
ES2285543T3 (es) 2003-11-05 2007-11-16 Ares Trading S.A. Procedimiento para la purificacion de la proteina de union a il-18.
WO2005047327A2 (fr) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. Variants de polypeptide se liant au recepteur fc neonatal (fcrn), proteines de liaison fc dimeres et techniques associees
US20050142133A1 (en) 2003-12-03 2005-06-30 Xencor, Inc. Optimized proteins that target the epidermal growth factor receptor
PT2418220T (pt) 2003-12-10 2017-10-04 Squibb & Sons Llc Anticorpos contra interferão alfa e suas utilizações
AR048210A1 (es) 2003-12-19 2006-04-12 Chugai Pharmaceutical Co Ltd Un agente preventivo para la vasculitis.
DOP2005000002A (es) 2004-01-09 2005-08-15 Pfizer "anticuerpos contra madcam"
CA2555688C (fr) 2004-02-11 2011-11-08 Warner-Lambert Company Llc Methodes de traitement de l'osteoarthrose avec des antagonistes de l'interleukine-6
EP3269738A1 (fr) 2004-03-24 2018-01-17 Chugai Seiyaku Kabushiki Kaisha Sous-types d'anticorps humanisés contre le récepteur de l'interleukine-6
AR048335A1 (es) 2004-03-24 2006-04-19 Chugai Pharmaceutical Co Ltd Agentes terapeuticos para trastornos del oido interno que contienen un antagonista de il- 6 como un ingrediente activo
KR20070035482A (ko) * 2004-03-24 2007-03-30 추가이 세이야쿠 가부시키가이샤 인터로킨-6 안타고니스트를 활성성분으로 함유하는내이장해 치료제
US7276585B2 (en) * 2004-03-24 2007-10-02 Xencor, Inc. Immunoglobulin variants outside the Fc region
US20050260711A1 (en) 2004-03-30 2005-11-24 Deepshikha Datta Modulating pH-sensitive binding using non-natural amino acids
WO2005112564A2 (fr) 2004-04-15 2005-12-01 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Régions variables d'anticorps humanisés et lignée germinale et méthodes de fabrication et d'utilisation
AR049390A1 (es) 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
EP1771205B1 (fr) 2004-06-18 2016-10-26 Ambrx, Inc. Nouveaux polypeptides de liaison a l'antigene et leurs utilisations
EP1773391A4 (fr) 2004-06-25 2009-01-21 Medimmune Inc Augmentation de la production d'anticorps de recombinaison dans des cellules de mamiferes par mutagenese sur le site
ATE528396T1 (de) 2004-07-06 2011-10-15 Bioren Inc Look-through-mutagenese zur entwicklung veränderter polypeptide mit verbesserten eigenschaften
EP3342782B1 (fr) 2004-07-15 2022-08-17 Xencor, Inc. Variantes optimisées de fc
EP1799718A1 (fr) 2004-09-14 2007-06-27 National Institute for Biological Standards and Control (NIBSC) Vaccin
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
WO2006047350A2 (fr) 2004-10-21 2006-05-04 Xencor, Inc. Variants d'immunoglobuline igg a fonction effectrice optimisee
EP1805320B1 (fr) * 2004-10-22 2014-09-03 Amgen Inc. Procedes de renaturation d'anticorps recombinants
US7462697B2 (en) 2004-11-08 2008-12-09 Epitomics, Inc. Methods for antibody engineering
AU2005335714B2 (en) * 2004-11-10 2012-07-26 Macrogenics, Inc. Engineering Fc antibody regions to confer effector function
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
JPWO2006067847A1 (ja) 2004-12-22 2008-06-12 中外製薬株式会社 フコーストランスポーターの機能が阻害された細胞を用いた抗体の作製方法
ES2343426T3 (es) 2004-12-23 2010-07-30 Novo Nordisk A/S Ligandos de afinidad de union a anticuerpos.
CA2592015A1 (fr) 2004-12-27 2006-07-06 Progenics Pharmaceuticals (Nevada), Inc. Anticorps antitoxines d'administration orale et leurs procedes de fabrication et d'utilisation
RU2481356C2 (ru) 2004-12-28 2013-05-10 Иннейт Фарма Моноклональные антитела против nkg2a
CA2595169A1 (fr) * 2005-01-12 2006-07-20 Xencor, Inc. Anticorps et proteines de fusion fc a immunogenicite modifiee
EP1847602B1 (fr) 2005-01-12 2014-04-23 Kyowa Hakko Kirin Co., Ltd. ANTICORPS IgG2 HUMAINS STABILISÉS
US20060263357A1 (en) 2005-05-05 2006-11-23 Tedder Thomas F Anti-CD19 antibody therapy for autoimmune disease
KR101374454B1 (ko) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
EP2824183B1 (fr) 2005-04-08 2020-07-29 Chugai Seiyaku Kabushiki Kaisha Procédé pour la production d'anticorps bispécifiques
PA8672101A1 (es) 2005-04-29 2006-12-07 Centocor Inc Anticuerpos anti-il-6, composiciones, métodos y usos
DK2573114T3 (en) 2005-08-10 2016-07-04 Macrogenics Inc The identification and production of antibodies with variant Fc regions, and methods of using same
US7888486B2 (en) 2005-08-19 2011-02-15 Wyeth Llc Antagonist antibodies against GDF-8
CA2622772A1 (fr) 2005-09-29 2007-04-12 Viral Logic Systems Technology Corp. Compositions immunomodulatrices et leurs utilisations
US8470316B2 (en) 2005-10-14 2013-06-25 Chugai Seiyaku Kabushiki Kaisha Agents for suppressing damage to transplanted islets after islet transplantation
RU2450830C2 (ru) 2005-10-21 2012-05-20 Чугаи Сейяку Кабусики Кайся Средства для лечения кардиопатии
EP1957531B1 (fr) 2005-11-07 2016-04-13 Genentech, Inc. Polypeptides de liaison comprenant des sequences diversifiees et des sequences consensus hypervariables vh/vl
AR057582A1 (es) 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
WO2007060411A1 (fr) 2005-11-24 2007-05-31 Ucb Pharma S.A. Anticorps anti-tnf alpha qui inhibent sélectivement le signal tnf alpha par le p55r
WO2007061029A1 (fr) 2005-11-25 2007-05-31 Keio University Agent thérapeutique pour le cancer de la prostate
JP5231810B2 (ja) * 2005-12-28 2013-07-10 中外製薬株式会社 抗体含有安定化製剤
SI3219328T1 (sl) 2005-12-29 2020-10-30 Janssen Biotech, Inc. Človeška protitelesa proti-IL-23, sestavki, postopki in uporabe
JP5033643B2 (ja) 2006-01-27 2012-09-26 学校法人慶應義塾 脈絡膜血管新生を伴う疾患の治療剤
JP2009525986A (ja) 2006-02-03 2009-07-16 メディミューン，エルエルシー タンパク質製剤
EP2006380A4 (fr) * 2006-03-23 2010-08-11 Kyowa Hakko Kirin Co Ltd Anticorps agoniste dirige contre le recepteur de la thrombopoietine humaine
JP5144499B2 (ja) * 2006-03-31 2013-02-13 中外製薬株式会社 二重特異性抗体を精製するための抗体改変方法
EP4793360A2 (fr) 2006-03-31 2026-08-19 Chugai Seiyaku Kabushiki Kaisha Procédés de régulation de la pharmacocinétique sanguine d'anticorps
JP5754875B2 (ja) * 2006-04-07 2015-07-29 国立大学法人大阪大学 筋再生促進剤
MX2008014842A (es) * 2006-05-25 2009-02-17 Glaxo Group Ltd Anticuerpos humanizados contra interleuquina-18 modificados.
US8080248B2 (en) 2006-06-02 2011-12-20 Regeneron Pharmaceuticals, Inc. Method of treating rheumatoid arthritis with an IL-6R antibody
ATE537190T1 (de) * 2006-06-02 2011-12-15 Regeneron Pharma Hochaffine antikörper gegen den humanen il-6- rezeptor
ES2544888T3 (es) 2006-06-08 2015-09-04 Chugai Seiyaku Kabushiki Kaisha Prevención o remedio para enfermedades inflamatorias
JP2010500876A (ja) 2006-08-18 2010-01-14 アブリンクス エン．ヴェー． Ｉｌ−６媒介性シグナル伝達に関連する疾患及び障害の治療のための、ｉｌ−６ｒに指向性を有するアミノ酸配列及びこれを含むポリペプチド
US8236313B2 (en) 2006-10-06 2012-08-07 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Prevention of tissue ischemia, related methods and compositions
US20100034194A1 (en) 2006-10-11 2010-02-11 Siemens Communications Inc. Eliminating unreachable subscribers in voice-over-ip networks
MX2009007830A (es) 2007-01-23 2009-10-07 Univ Shinshu Inhibidor de rechazo cronico.
WO2008092117A2 (fr) 2007-01-25 2008-07-31 Xencor, Inc. Nouvelles insertions, délétions et substitutions d'immunoglobulines
WO2008145141A1 (fr) 2007-05-31 2008-12-04 Genmab A/S Procédé d'extension de la demi-vie de molécules exogènes ou endogènes solubles
BRPI0812508B1 (pt) * 2007-06-18 2019-06-25 Inventio Aktiengesellschaft Dispositivo de freio para um acionamento de elevador
CN104076100A (zh) 2007-06-29 2014-10-01 奎斯特诊断投资公司 用液相层析-质谱法分析体液内的氨基酸
WO2009010539A2 (fr) 2007-07-19 2009-01-22 Ablynx. N.V. Recepteur de l'interleukine-6 (il-6) derive de macaca fascicularis
EP2174667B1 (fr) 2007-07-26 2017-01-04 Osaka University Agent pour le traitement de l'ophtalmie contenant un inhibiteur du récepteur de l'interleukine 6 en tant qu'ingrédient actif
EP2031064A1 (fr) 2007-08-29 2009-03-04 Boehringer Ingelheim Pharma GmbH & Co. KG Procédé d'augmentation de titres de protéines
JP5963341B2 (ja) 2007-09-14 2016-08-10 アムジエン・インコーポレーテツド 均質な抗体集団
RU2505603C2 (ru) 2007-09-26 2014-01-27 Чугаи Сейяку Кабусики Кайся Антитело против рецептора il-6
ES2687808T3 (es) 2007-09-26 2018-10-29 Chugai Seiyaku Kabushiki Kaisha Región constante de anticuerpo modificado
EP3127921A1 (fr) 2007-09-26 2017-02-08 Chugai Seiyaku Kabushiki Kaisha Procédé de modification d'un anticorps par point isoélectrique par substitution d'acide aminé dans cdr
WO2009041734A1 (fr) 2007-09-26 2009-04-02 Kyowa Hakko Kirin Co., Ltd. Anticorps agoniste anti-récepteur de la thrombopoïétine humaine
KR20150126724A (ko) 2007-09-28 2015-11-12 추가이 세이야쿠 가부시키가이샤 혈장 중 반응속도가 개선된 항-글리피칸-3 항체
BRPI0817482B8 (pt) 2007-10-02 2021-05-25 Chugai Pharmaceutical Co Ltd uso de um anticorpo do receptor da interleucina-6 (il-6) no tratamento da doença do enxerto versus hospedeiro (gvhd)
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
TWI548418B (zh) 2007-12-05 2016-09-11 中外製藥股份有限公司 Anti-NR10 / IL-31RA antibody and its use
WO2009085200A2 (fr) 2007-12-21 2009-07-09 Amgen Inc. Anticorps anti-amyloïde et utilisations de ceux-ci
MX2010008578A (es) 2008-02-08 2010-11-10 Medimmune Llc Anticuerpos anti-receptor 1 de interferon alfa con afinidad reducida al ligando fc.
TW201920257A (zh) 2008-04-11 2019-06-01 日商中外製藥股份有限公司 重複結合複數個抗原的抗原結合分子
WO2009139822A1 (fr) 2008-05-01 2009-11-19 Amgen Inc. Anticorps anti-hepcidine et méthodes d’utilisation associées
TW201503898A (zh) 2008-06-05 2015-02-01 Chugai Pharmaceutical Co Ltd 神經浸潤抑制劑
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
AU2009303526B2 (en) 2008-10-14 2015-01-15 Genentech, Inc. Immunoglobulin variants and uses thereof
KR20110091780A (ko) 2008-11-25 2011-08-12 앨더 바이오파마슈티컬즈, 인코포레이티드 악액질, 쇠약, 피로 및／또는 발열을 예방하거나 치료하는 ｉｌ­６의 길항제
EP2400981A4 (fr) 2009-02-26 2013-02-27 Lpath Inc Conception d'anticorps humanisé anti-facteur d'activation plaquettaire à l'aide de modèles d'anticorps anti-lipide
RU2565809C2 (ru) 2009-03-19 2015-10-20 Чугаи Сейяку Кабусики Кайся Фармацевтический состав, содержащий молекулы антител с улучшенными свойствами
TWI457134B (zh) 2009-03-19 2014-10-21 Chugai Pharmaceutical Co Ltd Rheumatoid arthritis treatment
JP5717624B2 (ja) 2009-03-19 2015-05-13 中外製薬株式会社 抗体定常領域改変体
TWI544077B (zh) * 2009-03-19 2016-08-01 中外製藥股份有限公司 Antibody constant region change body
SG178190A1 (en) 2009-07-31 2012-03-29 Shin Maeda Cancer metastasis inhibitor
US10150808B2 (en) * 2009-09-24 2018-12-11 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant regions
JP6101489B2 (ja) 2010-01-28 2017-03-22 アブ バイオサイエンシズ インコーポレイテッド 親和性が低下した抗体およびそれを作製する方法
EP3053932B1 (fr) 2010-02-19 2020-07-22 Xencor, Inc. Nouvelles immunoadhésines ctla4-ig
EP2543730B1 (fr) 2010-03-04 2018-10-31 Chugai Seiyaku Kabushiki Kaisha Variante de région constante d'anticorps
NZ602220A (en) 2010-03-11 2014-10-31 Rinat Neuroscience Corp Antibodies with ph dependent antigen binding
TWI667346B (zh) 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的FcRn親和力之抗體
JP5904552B2 (ja) 2010-05-28 2016-04-13 国立研究開発法人国立がん研究センター 膵癌治療剤
RS63800B1 (sr) 2010-05-28 2022-12-30 Chugai Pharmaceutical Co Ltd Poboljšanje antitumorskog odgovora t ćelije
KR101933197B1 (ko) 2010-11-08 2018-12-27 제넨테크, 인크. 피하 투여용 항―ｉｌ―6 수용체 항체
WO2012063875A1 (fr) 2010-11-11 2012-05-18 シスメックス株式会社 Marqueurs de détection des cellules t auxiliaires folliculaires humaines et procédé de détection des cellules t auxiliaires folliculaires humaines
TWI654203B (zh) 2010-11-30 2019-03-21 Chugai Seiyaku Kabushiki Kaisha 具有鈣依存性的抗原結合能力之抗體
SG10201609665PA (en) 2011-02-25 2017-01-27 Chugai Pharmaceutical Co Ltd FcɣRIIb-SPECIFIC Fc ANTIBODY
RU2013140975A (ru) 2011-02-28 2015-04-10 Дженентек, Инк. Биологические маркеры и способы прогнозирования восприимчивости к антагонистам в-клеток
TW201817745A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
JP6322411B2 (ja) 2011-09-30 2018-05-09 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
EP2765192A4 (fr) 2011-10-05 2015-04-15 Chugai Pharmaceutical Co Ltd Molécule se liant à l'antigène pour favoriser la clairance du plasma d'un antigène comprenant un domaine de liaison aux récepteurs de type chaîne saccharidique
KR20210074395A (ko) 2011-11-30 2021-06-21 추가이 세이야쿠 가부시키가이샤 면역 복합체를 형성하는 세포내로의 운반체（캐리어）를 포함하는 의약
CA2865158C (fr) 2012-02-24 2022-11-01 Chugai Seiyaku Kabushiki Kaisha Molecule de liaison d'antigene destinee a favoriser la disparition d'antigene via le recepteur fc.gamma.riib
JPWO2013180201A1 (ja) 2012-05-30 2016-01-21 中外製薬株式会社 会合化した抗原を消失させる抗原結合分子
NZ704771A (en) 2012-08-13 2018-02-23 Regeneron Pharma Anti-pcsk9 antibodies with ph-dependent binding characteristics
US20160032014A1 (en) 2013-03-15 2016-02-04 Amgen Inc. Human antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9
US9321686B2 (en) 2013-03-15 2016-04-26 Forta Corporation Reinforcement fiber coating compositions, methods of making and treating, and uses for improved adhesion to asphalt and portland cement concrete
SG11201508170TA (en) 2013-04-02 2015-11-27 Chugai Pharmaceutical Co Ltd Fc REGION VARIANT
EP3009518B1 (fr) 2013-06-11 2020-08-12 National Center of Neurology and Psychiatry Procédé permettant de prédire le pronostic post-thérapie d'un patient atteint de sclérose en plaques à périodes progressives et rémittentes (spppr) et procédé permettant de déterminer l'applicabilité d'une nouvelle thérapie
NZ711451A (en) 2014-03-07 2016-05-27 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
TWI759261B (zh) 2015-02-27 2022-04-01 日商中外製藥股份有限公司 Ｉｌ－６受體抗體用於製備醫藥組成物的用途
JP6875683B2 (ja) 2015-05-19 2021-05-26 国立研究開発法人国立精神・神経医療研究センター 多発性硬化症（ｍｓ）患者の新規治療適用判断方法

Also Published As

Publication number Publication date
PE20120079A1 (es) 2012-02-29
CA2763039A1 (fr) 2010-04-01
PT2330193E (pt) 2015-09-21
US20150166666A1 (en) 2015-06-18
KR101044180B1 (ko) 2011-06-24
NL301152I2 (nl) 2022-01-13
SI2330193T1 (sl) 2015-10-30
HK1185887A1 (en) 2014-02-28
JP4550938B2 (ja) 2010-09-22
US20240010738A1 (en) 2024-01-11
US20220306755A1 (en) 2022-09-29
FR21C1054I2 (fr) 2022-10-21
MY153908A (en) 2015-04-15
US20250101118A1 (en) 2025-03-27
NL301152I1 (fr) 2021-12-15
CR20110204A (es) 2011-06-03
HRP20150857T1 (hr) 2015-10-09
EP2330193B1 (fr) 2015-06-17
LTC2330193I2 (fr) 2022-10-10
LUC00241I2 (fr) 2025-02-03
US20230159648A1 (en) 2023-05-25
FIC20210049I1 (fi) 2021-12-13
CN101849006A (zh) 2010-09-29
RU2430111C1 (ru) 2011-09-27
NZ592214A (en) 2012-09-28
US20110098450A1 (en) 2011-04-28
BRPI0905076B1 (pt) 2021-01-05
TW201021829A (en) 2010-06-16
AR127010A2 (es) 2023-12-06
AU2009290162B2 (en) 2011-11-10
FR21C1054I1 (fr) 2021-12-24
PL2330193T3 (pl) 2015-11-30
CL2011000632A1 (es) 2011-06-03
IL211850A0 (en) 2011-06-30
EP2330193A4 (fr) 2012-07-25
CA2763039C (fr) 2015-10-27
US20120253016A1 (en) 2012-10-04
BRPI0905076A2 (pt) 2015-07-07
CO6362048A2 (es) 2012-01-20
KR20100061834A (ko) 2010-06-09
US20220041741A1 (en) 2022-02-10
AR073404A1 (es) 2010-11-03
RU2430111C3 (ru) 2022-03-31
ES2546800T3 (es) 2015-09-29
BRPI0905076B8 (pt) 2021-05-25
TWI440469B (zh) 2014-06-11
CN103254310A (zh) 2013-08-21
JPWO2010035769A1 (ja) 2012-02-23
US8562991B2 (en) 2013-10-22
ECSP11011003A (es) 2011-05-31
CN101849006B (zh) 2013-05-22
CN103254310B (zh) 2015-08-12
JP5661291B2 (ja) 2015-01-28
KR101690334B1 (ko) 2017-01-09
CA2699834A1 (fr) 2010-04-01
LTPA2021013I1 (fr) 2021-12-10
NO2021048I1 (no) 2021-11-11
HUE027533T2 (en) 2016-11-28
CA2699834C (fr) 2012-03-13
US10662245B2 (en) 2020-05-26
US20200231688A1 (en) 2020-07-23
HUS2100050I1 (hu) 2021-12-28
ZA201103027B (en) 2012-06-26
HK1147107A1 (en) 2011-07-29
MX2010003256A (es) 2010-08-04
US20250346677A1 (en) 2025-11-13
EP2330193A1 (fr) 2011-06-08
AU2009290162A1 (en) 2010-04-15
KR20110046385A (ko) 2011-05-04
WO2010035769A1 (fr) 2010-04-01
DK2330193T3 (en) 2015-08-24
US20240301075A1 (en) 2024-09-12
JP2010239958A (ja) 2010-10-28

Similar Documents

Publication Publication Date Title
CN102438653B (zh) 预防或治疗恶病质、虚弱、疲劳和/或发烧il-6拮抗剂
AR127010A2 (es) Anticuerpo, moléculas relacionadas, célula huesped, método de preparación y composición farmacéutica
US20200354446A1 (en) Antagonists of il-6 to prevent or treat cachexia, weakness, fatigue, and /or fever
EP3689370B1 (fr) Anticorps anti-gdf15
CN115894703A (zh) 具有经修饰重链恒定区的多特异性重链抗体
US20220242950A1 (en) Anti-IL1RAP antibody
CN108271372A (zh) Il-8-结合抗体及其应用
CN107108729A (zh) 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il‑8‑结合抗体，及其应用
TWI868154B (zh) 用於與細胞激素抑制劑組合使用之抗t細胞抗原結合分子
EP3381944A1 (fr) Anticorps anti-pcsk9 et son utilisation
CN112638940B (zh) 抗-il-25抗体及其用途
FR2978964A1 (fr) Composition vaccinale anti-il-6
Arutla et al. Prescreening of nicotine hapten linkers in vitro to select hapten-conjugate vaccine candidates for pharmacokinetic evaluation in vivo
WO2016131772A1 (fr) Procédé et appareil de conception de protéines
UA101221C2 (ru) Молекулы улучшенного антитела
TW201012830A (en) Method of modifying isoelectric point of antibody via amino acid substitution in CDR
MX2011005406A (es) Antagonistas de il-6 para prevenir o tratar la caquexia, la debilidad, la fatiga y/o la fiebre.
HK40074985A (zh) 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用
AU2013203879A1 (en) Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue and/or fever